Takeda Pharmaceutical Company Limited (TAK)

NYQ – Real Time Price. Currency in USD

17.42

-0.07 (-0.37%)

At close: Aug 12, 2026, 3:59 PM EDT

17.60

+0.19 (1.09%)

After-hours: Aug 12, 2026, 4:34 PM EDT

07.08.2026

Takeda's Pipeline Looks Encouraging, But Generic Erosion Is A Near-Term Concern

Takeda Pharmaceuticals (TAK) remains a hold, with shares near 52-week highs and uncertainty about a major successor to Entyvio. TAK's Q1 showed 10% revenue growth, but bottom-line weakness from higher taxes and lower operating cash flow due to mounting receivables. Orzeyful's FDA approval is promising, but its commercial impact is likely limited compared to Entyvio; pipeline drugs like zasocitinib offer longer-term potential, but how much is as yet uncertain.

06.08.2026

Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Takeda Pharmaceutical Co. Ltd.‘s (NYSE:TAK) Orzeyful (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.

05.08.2026

U.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people's lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to tr.

05.08.2026

US FDA approves Takeda's sleep disorder pill

The FDA has approved Takeda Pharmaceuticals' oral drug for narcolepsy, the U.S. health regulator said on Wednesday, backing ‌the first treatment that targets all the symptoms of the rare sleep disorder.

Videos

No Data

There is no data to display

Press releases

05.08.2026

Takeda Pharmaceutical Company Limited (TAK)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Takeda Pharmaceutical Company Limited (TAK)

Takeda's Pipeline Looks Encouraging, But Generic Erosion Is A Near-Term Concern

Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval

U.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

US FDA approves Takeda's sleep disorder pill

Videos

No Data

Press releases

U.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Takeda's Pipeline Looks Encouraging, But Generic Erosion Is A Near-Term Concern

Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval

U.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

US FDA approves Takeda's sleep disorder pill

Videos

No Data

Press releases

U.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Search stocks

Takeda Pharmaceutical Company Limited (TAK)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Takeda Pharmaceutical Company Limited (TAK)

Takeda's Pipeline Looks Encouraging, But Generic Erosion Is A Near-Term Concern

Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval

U.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

US FDA approves Takeda's sleep disorder pill

Videos

No Data

Press releases

U.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Takeda's Pipeline Looks Encouraging, But Generic Erosion Is A Near-Term Concern

Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval

U.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

US FDA approves Takeda's sleep disorder pill

Videos

No Data

Press releases

U.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1